Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Patients Under 18 With Relapsed or Refractory Solid Tumors

    Recruiting

    1 1 1
    Investigated Drugs:
    Belgium Denmark France Germany Hungary Italy +2
  • Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

    Recruiting

    2 1 1
    Investigated Diseases:
    Denmark France Spain
  • EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    Austria Belgium Finland France Germany Italy +4
  • Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Germany Italy
  • Phase 1/2A Study of OTP-01 to Evaluate Safety and Anti‑Tumor Activity in Patients with Advanced Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    Ireland Portugal Spain
  • A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

    Recruiting

    2 1 1 1
    Investigated Drugs:
    France Ireland Portugal Spain
  • A Study of Valemetostat Tosylate in Adult Patients with Advanced Solid Tumors That Have Specific Gene Changes or Are Clear Cell Endometrial or Ovarian Cancers

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • A Study Testing How Pralsetinib Affects Other Medications in Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain
  • Testing GSK5764227 combined with standard cancer treatments in patients with advanced solid tumors to evaluate safety and effectiveness

    Recruiting

    1 1 1 1
    Investigated Diseases:
    Spain
  • A Study of CRN09682 for Patients with Neuroendocrine Tumors and Other Solid Tumors that Express Somatostatin Receptor Type 2

    Recruiting

    2 1 1
    Investigated Diseases:
    France Germany Italy Spain